Nasdaq: ALMR · Listed Apr 17, 2026
Alamar Biosciences IPO
IPO price
$17.00
Alamar Biosciences (ALMR) priced its IPO at $17.00 a share and has traded on Nasdaq since Apr 17, 2026.
ALMR today$30.51+79.47%since IPO15-min delayed · as of 7:30:03 PM EST on Nov 18, 2026
See the ALMR quoteFirst trading day · Apr 17, 2026
- IPO price
- $17.00
- the top of the range of $15 to $17
- First trade
- $22.60
- +32.94% from the IPO price
- First-day last trade
- $22.53
- +32.53% from the IPO price, regular session
- Raise
- $191.25M
- before the underwriters' option
These numbers are from the first trading day, Apr 17, 2026.
How ALMR did against the market
ALMR against the market, from its first trade at 12:30 ET to the last trade of the session.
- ALMR from its first trade
- -0.31%
- Against the market (QQQ)
- -0.2 pts
ALMR fell 0.3% from its first trade to the last trade of the session. That is 0.2 points worse than the market.
Same-day moves do not show that ALMR caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
ALMR against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
ALMR against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| Alamar Biosciences '26 | $191.25M | +32.94% | +32.53% | +42.94% | +20.35% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The Alamar Biosciences IPO offers 11.25M shares to raise $191.25M, before any underwriters' option.
- Expected price range
- $15 to $17
- IPO price
- $17.00
- Shares offered
- 11.25M
- Money raised
- $191.25M
- Listing date
- Apr 17, 2026
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- Alamar Biosciences$191.25M
Where ALMR ranks
Alamar Biosciences's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- ALMR$2.12B
ALMR news
The latest news and headlines about Alamar Biosciences (ALMR).
- Alamar (ALMR) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatespositiveZacks Investment Research· Nov 3, 2026
- UPDATE -- Alamar Biosciences and Nightingale Health to Lead UK Biobank 80,000-Sample Neurodegenerative Disease StudypositiveGlobeNewswire Inc.· Nov 2, 2026
- Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s TreatmentpositiveGlobeNewswire Inc.· Sep 24, 2026
- Alamar Biosciences 联合多所顶尖研究型大学推出全国性研究计划,推进神经退行性疾病血液生物标志物相关研究positiveGlobeNewswire Inc.· Jul 13, 2026
- Alamar Biosciences 與多間頂尖研究大學合作啟動全國計劃,旨在推動神經退行性疾病相關的血漿生物標記研究positiveGlobeNewswire Inc.· Jul 13, 2026
- Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative DiseasespositiveGlobeNewswire Inc.· Jul 13, 2026
Filings and the company
What Alamar Biosciences has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Alamar Biosciences discloses to the SEC on Form 8-K.
- Executive officer departureNov 3, 2026
After more than five years of exemplary service, on October 30, 2026, Timothy "Tod" White informed the Company that he will retire from his current position as President of the Company, effective as of December 31, 2026.
- Director appointmentSep 1, 2026
On August 28, 2026, the board of directors (the "Board") of Alamar Biosciences, Inc. (the "Company") appointed Robert Ragusa to the Board, effective as of September 1, 2026. Mr. Ragusa will serve as a Class I Director, with an initial term expiring at the Company's 2027 Annual Meeting of Stockholders. Mr. Ragusa was also appointed to the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee of the Board.
- Director departureJul 15, 2026
Ian Ratcliffe, a member of the Company's board of directors (the "Board"), passed away on July 5, 2026. Mr. Ratcliffe served as an independent director on the Board since February 2024.
- Public offeringApr 20, 2026
On April 20, 2026, the Company completed its IPO of an aggregate of 12,937,500 shares of common stock (which includes the exercise in full of the underwriters' option to purchase an additional 1,687,500 shares of common stock) at a price to the public of $17.00 per share. The aggregate gross proceeds from the IPO, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, was approximately $219.9 million.
About Alamar Biosciences
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
- Ticker
- ALMR
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- LABORATORY ANALYTICAL INSTRUMENTS
- Listed
- Apr 17, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the Alamar Biosciences IPO price?
$17.00 a share.
When did Alamar Biosciences go public?
Alamar Biosciences listed on Nasdaq on Apr 17, 2026 under the ticker ALMR.
How much did the Alamar Biosciences IPO raise?
$191.25M, before any underwriters' option.
How did Alamar Biosciences open on its first day?
ALMR first traded at $22.60, +32.94% from the IPO price of $17.00.
How did ALMR close on its first day?
Its last regular-session trade was $22.53, +32.53% from the IPO price of $17.00.
What was the ALMR first-day trading range?
$21.50 to $24.50 in the regular session.
How many ALMR shares traded on the first day?
4.76M shares in the regular session.
How many shares did Alamar Biosciences sell in its IPO?
11.25M shares.
How did ALMR do against the market on its first day?
ALMR fell 0.3% from its first trade to the last trade of the session. That is 0.2 points worse than the market (QQQ, the Nasdaq-100 ETF).
What exchange is ALMR listed on?
Alamar Biosciences lists on Nasdaq under the ticker ALMR.
Build with Massive
Get the ALMR data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/ALMR/range/5/minute |
| Market cap | /v3/reference/tickers/ALMR |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.